Glenn Miller
11Patents
8h-index
4Co-inventors
61Inventor score
Filing activity: Oct 21, 1992 → Jun 28, 2006
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6300314A | Hematopoietic stimulation | Human Necessities | 78 | Expired |
| US5547853A | CD2-binding domain of lymphocyte function associated antigen 3 | Emerging Cross-Sectional Technologies | 35 | Expired |
| US6890904B1 | Anti-tumor agents | Human Necessities | 34 | Expired |
| US6949514B2 | Anti-tumor agents | Human Necessities | 16 | Expired |
| US6770628B2 | Hematopoietic stimulation | Human Necessities | 16 | Expired |
| US5914111A | CD2-binding domain of lymphocyte function associated antigen-3 | Emerging Cross-Sectional Technologies | 10 | Expired |
| US5728677A | Methods of inhibiting T-cell dependent proliferation of peripheral blood lymphocytes using the CD2-binding domain of lymphocyte function associated antigen 3 | Emerging Cross-Sectional Technologies | 8 | Expired |
| US7282484B2 | Anti-tumor agents | Human Necessities | 8 | Active |
| US5928643A | Method of using CD2-binding domain of lymphocyte function associated antigen 3 to initiate T cell activation | Chemistry; Metallurgy | 7 | Expired |
| US7067489B2 | Hematopoietic stimulation | Human Necessities | 5 | Expired |
| US7259138B2 | Anti-tumor agents | Human Necessities | 4 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.